CL2019001421A1 - Fármaco terapéutico o fármaco profiláctico para la nefropatía diabética. - Google Patents

Fármaco terapéutico o fármaco profiláctico para la nefropatía diabética.

Info

Publication number
CL2019001421A1
CL2019001421A1 CL2019001421A CL2019001421A CL2019001421A1 CL 2019001421 A1 CL2019001421 A1 CL 2019001421A1 CL 2019001421 A CL2019001421 A CL 2019001421A CL 2019001421 A CL2019001421 A CL 2019001421A CL 2019001421 A1 CL2019001421 A1 CL 2019001421A1
Authority
CL
Chile
Prior art keywords
drug
diabetic nephropathy
prophylactic
therapeutic
therapeutic drug
Prior art date
Application number
CL2019001421A
Other languages
English (en)
Spanish (es)
Inventor
Takashi Shirakura
Shunsuke Tsujimoto
Yoshiki Tsubosaka
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of CL2019001421A1 publication Critical patent/CL2019001421A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2019001421A 2016-11-28 2019-05-24 Fármaco terapéutico o fármaco profiláctico para la nefropatía diabética. CL2019001421A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016229972 2016-11-28

Publications (1)

Publication Number Publication Date
CL2019001421A1 true CL2019001421A1 (es) 2019-08-30

Family

ID=62195148

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001421A CL2019001421A1 (es) 2016-11-28 2019-05-24 Fármaco terapéutico o fármaco profiláctico para la nefropatía diabética.

Country Status (17)

Country Link
US (1) US20190374515A1 (zh)
EP (1) EP3545954A4 (zh)
JP (2) JP6861726B2 (zh)
KR (1) KR20190073473A (zh)
CN (1) CN109982697A (zh)
AU (1) AU2017364804A1 (zh)
BR (1) BR112019008388A2 (zh)
CA (1) CA3039890A1 (zh)
CL (1) CL2019001421A1 (zh)
CO (1) CO2019005512A2 (zh)
IL (1) IL266311A (zh)
MA (1) MA46909A (zh)
MX (1) MX2019005867A (zh)
PH (1) PH12019501027A1 (zh)
RU (1) RU2735538C1 (zh)
TW (1) TW201828939A (zh)
WO (1) WO2018097294A1 (zh)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008118156A (ru) * 2005-10-07 2009-11-20 Астеллас Фарма Инк. (Jp) Производное триарилкарбоновой кислоты
TWI437986B (zh) * 2008-01-31 2014-05-21 R Tech Ueno Ltd 噻唑衍生物及使用該衍生物作為ｖａｐ－１抑制劑之用途
MX361138B (es) * 2010-06-16 2018-11-28 Takeda Pharmaceuticals Usa Inc Formas novedosas de dosificacion de liberacion modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa.
JP5862897B2 (ja) 2010-11-01 2016-02-16 株式会社三和化学研究所 腎機能障害の予防又は治療に用いる医薬
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
CN103848796A (zh) * 2012-11-30 2014-06-11 镇江新元素医药科技有限公司(中外合资) 一类氘代2-苯基噻唑化合物及其药物组合物
TWI606048B (zh) * 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
ES2884123T3 (es) * 2013-03-15 2021-12-10 Xortx Therapeutics Inc Formulaciones de inhibidores de xantina oxidasa
JP6134072B2 (ja) * 2014-07-30 2017-05-24 帝人ファーマ株式会社 キサンチンオキシダーゼ阻害薬

Also Published As

Publication number Publication date
AU2017364804A1 (en) 2019-05-02
PH12019501027A1 (en) 2019-12-16
IL266311A (en) 2019-06-30
CA3039890A1 (en) 2018-05-31
CO2019005512A2 (es) 2019-07-31
RU2735538C1 (ru) 2020-11-03
BR112019008388A2 (pt) 2019-07-09
MX2019005867A (es) 2019-08-14
JPWO2018097294A1 (ja) 2019-07-11
JP2021028335A (ja) 2021-02-25
EP3545954A1 (en) 2019-10-02
EP3545954A4 (en) 2019-12-04
JP6861726B2 (ja) 2021-04-21
CN109982697A (zh) 2019-07-05
MA46909A (fr) 2021-05-05
US20190374515A1 (en) 2019-12-12
TW201828939A (zh) 2018-08-16
WO2018097294A1 (ja) 2018-05-31
KR20190073473A (ko) 2019-06-26

Similar Documents

Publication Publication Date Title
CY1124431T1 (el) Συριγγα
GT201700146A (es) Compuestos de triazolopirimidina y usos de los mismos
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CL2019000844A1 (es) Compuesto de piridina.
DOP2016000233A (es) MODULADORES ALOSTÉRICOS DE PROTElNA NÚCLEO DE HEPATITIS B
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
BR112018010118A2 (pt) inibidores de cxcr2
CL2017000170A1 (es) Conjugados de fármacos con anticuerpos anti-cdh6
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY36075A (es) Derivados de tubulisina
CU24493B1 (es) Complejo de torio dirigido a tejido
BR112017009289A2 (pt) métodos de administrar composições de amantadina
CO2017005566A2 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
CL2017000944A1 (es) Compuesto heterocíclico
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
BR112016011899A2 (pt) Processo para preparação de 5-fluoro-1h-pirazóis
BR112018012116A2 (pt) terapia intravesical para câncer de bexiga
EA201691036A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
CL2019001421A1 (es) Fármaco terapéutico o fármaco profiláctico para la nefropatía diabética.
CL2018000489A1 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
DOP2017000196A (es) Derivados de tetrahidropiranil benzamida